1. NCCN clinical practice guidelines in oncology (NCCN guidelines®) breast cancer, version 3.2019.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
.
2. NCCN clinical practice guidelines in oncology (NCCN guidelines®) cutaneous melanoma, version 2.2019.
https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
.
3. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.
4. Giammarile F, Vidal-Sicart S, Orsini F, et al. In: Volterrani D, Erba PA, Carrió I, Strauss HW, Mariani G, editors. Nuclear medicine textbook—methodology and clinical applications. Basel: Springer Nature; 2019. p. 351–90.
5. Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385–93.